The short answer
Bacopa has not been shown to cause a clinically important interaction with thioridazine. Its laboratory enzyme effects do not establish the strong CYP2D6 inhibition that triggers thioridazine’s serious heart-rhythm warning.
What this answer covers
Oral thioridazine with the exact supplement preparation described.
- Supplement or preparation
- Bacopa monnieri
- Medication ingredient
- thioridazine
Thioridazine’s enzyme warning is serious and specific
Thioridazine levels can rise with CYP2D6 inhibition, increasing the risk of potentially fatal abnormal heart rhythms. This warning makes the complete medication and supplement list important, but each proposed inhibitor needs relevant evidence.
The Bacopa experiment was a laboratory assay
A standardized methanolic Bacopa extract inhibited some enzymes in vitro. Its CYP2D6 inhibition was weak and required much higher concentrations; isolated bacosides had negligible effects in the tested assays. No participants received thioridazine.
Other assays do not confirm a strong clinical effect
Another extract study interpreted its observed inhibition as negligible interaction potential. These preparation-dependent laboratory results neither establish a clinical contraindication nor prove every Bacopa product is safe with thioridazine.
Have the product reviewed before adding it
Because thioridazine has a narrow margin for rhythm-related interactions, ask the prescriber or pharmacist about the exact extract. Follow the prescribed heart-rhythm and electrolyte monitoring plan; do not change the dose based on a laboratory prediction.
Evidence and practical considerations
Side effects & toxicity
Bacopa has not been shown to cause a clinically important interaction with thioridazine. Its laboratory enzyme effects do not establish the strong CYP2D6 inhibition that triggers thioridazine’s serious heart-rhythm warning.
- Exact scope
- Oral thioridazine with the exact supplement preparation described. with Oral thioridazine with the stated label and formulation limits.
- Medication form and route
- oral
What remains uncertain
- The Bacopa assay found weak CYP2D6 inhibition at high concentrations and negligible isolated-bacoside effects. Another assay was interpreted as showing negligible interaction potential. No exact clinical exposure or QT effect was measured; effects on other enzymes do not establish a clinical CYP2D6 contraindication.
Factors that may matter: Exact preparation and amount; Other medicines; Seizure history, alertness or electrolyte status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral thioridazine.
CYP2D6 inhibition or reduced activity can increase thioridazine exposure and potentially fatal QT-related arrhythmias. Baseline ECG and potassium testing, potassium correction before treatment and periodic monitoring are recommended. Drowsiness and rare seizures are described.
How this applies: Exact ingredient and oral-route clinical context.
Label class warnings do not establish every exact botanical interaction, event rate or protective supplement interval.
Source 2: Original laboratory study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Recombinant human CYP enzymes in a laboratory assay.
The extract inhibited several enzymes in vitro, but CYP2D6 inhibition was weak at much higher concentrations. Isolated bacosides had negligible inhibition in the tested assays.
How this applies: Does not establish a clinically important CYP2D6 interaction despite thioridazine’s serious inhibitor warning.
No thioridazine or human pharmacokinetic trial. Modeled intestinal concentration is not measured clinical exposure.
Source 3: Original laboratory study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Human CYP enzyme assays of several Ayurvedic plant extracts.
The authors interpreted the observed inhibition as negligible interaction potential under their assay conditions.
How this applies: Contrary experimental context prevents a universal strong-inhibitor label.
Laboratory assays and preparation differences; not proof of clinical safety with thioridazine.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked draft with exact preparation limits, original study findings and uncertainty. Clinical review not recorded. | |
| Research summary published |
Article revision: 89cc4103a0c8c4a4
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.